DK2293797T3 - PROGESTERON ANTAGONISTS SUCH AS CDB-4124 TO REDUCE PAIN CONNECTED WITH ENDOMETRIOSIS AND UTERUS FIBROMES - Google Patents

PROGESTERON ANTAGONISTS SUCH AS CDB-4124 TO REDUCE PAIN CONNECTED WITH ENDOMETRIOSIS AND UTERUS FIBROMES Download PDF

Info

Publication number
DK2293797T3
DK2293797T3 DK09739520.6T DK09739520T DK2293797T3 DK 2293797 T3 DK2293797 T3 DK 2293797T3 DK 09739520 T DK09739520 T DK 09739520T DK 2293797 T3 DK2293797 T3 DK 2293797T3
Authority
DK
Denmark
Prior art keywords
cdb
progesterone
endometrial
administered
administration
Prior art date
Application number
DK09739520.6T
Other languages
Danish (da)
English (en)
Inventor
Joseph S Podolski
Original Assignee
Repros Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Repros Therapeutics Inc filed Critical Repros Therapeutics Inc
Application granted granted Critical
Publication of DK2293797T3 publication Critical patent/DK2293797T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
DK09739520.6T 2008-04-28 2009-04-27 PROGESTERON ANTAGONISTS SUCH AS CDB-4124 TO REDUCE PAIN CONNECTED WITH ENDOMETRIOSIS AND UTERUS FIBROMES DK2293797T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4847208P 2008-04-28 2008-04-28
PCT/US2009/041826 WO2009134718A1 (en) 2008-04-28 2009-04-27 Pregesteron antagonists such as cdb-4124 in the treatment of endometriosis, uterine fibroids, dysmenorrhea, breast cancer etc

Publications (1)

Publication Number Publication Date
DK2293797T3 true DK2293797T3 (en) 2016-01-11

Family

ID=40751037

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09739520.6T DK2293797T3 (en) 2008-04-28 2009-04-27 PROGESTERON ANTAGONISTS SUCH AS CDB-4124 TO REDUCE PAIN CONNECTED WITH ENDOMETRIOSIS AND UTERUS FIBROMES

Country Status (24)

Country Link
US (2) US8426394B2 (enExample)
EP (1) EP2293797B1 (enExample)
JP (1) JP5791499B2 (enExample)
KR (2) KR20110014162A (enExample)
CN (2) CN105616427A (enExample)
AR (1) AR071516A1 (enExample)
AU (1) AU2009241355B2 (enExample)
BR (1) BRPI0911563A2 (enExample)
CA (1) CA2722753C (enExample)
CL (1) CL2009001010A1 (enExample)
DK (1) DK2293797T3 (enExample)
EA (3) EA032646B1 (enExample)
ES (1) ES2561810T3 (enExample)
IL (1) IL208844A0 (enExample)
ME (1) ME01123B (enExample)
MX (1) MX2010011272A (enExample)
MY (1) MY161059A (enExample)
NI (1) NI201000183A (enExample)
NZ (1) NZ589533A (enExample)
SG (1) SG10201408483QA (enExample)
TW (1) TWI477276B (enExample)
UA (1) UA102849C2 (enExample)
WO (1) WO2009134718A1 (enExample)
ZA (1) ZA201007529B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI477276B (zh) 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
TWI539953B (zh) * 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法
HUP0900487A2 (hu) * 2009-08-05 2011-03-28 Richter Gedeon Nyrt 17-acetoxi-11ß-[4-(dimetil-amino)-fenil]-21-metoxi-19-norpregna-4,9-dién-3,20-dion új kristályos polimorf módosulata és eljárás elõállítására
UA113283C2 (xx) * 2010-12-23 2017-01-10 19-норстероїди і їх застосування для лікування прогестеронзалежних станів
EP2471537A1 (en) 2010-12-30 2012-07-04 PregLem S.A. Treatment of pain associated with dislocation of basal endometrium
RS62297B1 (sr) 2011-11-23 2021-09-30 Therapeuticsmd Inc Prirodne kombinovane hormonske supstitucione formulacije i terapije
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
SG10201704858PA (en) 2012-05-31 2017-07-28 Repros Therapeutics Inc Formulations and methods for vaginal delivery of antiprogestins
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
EP2914268B1 (en) * 2012-11-02 2018-07-04 Repros Therapeutics Inc. Methods and compositions for treating progesterone-dependent conditions
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
HU230381B1 (hu) * 2014-02-17 2016-03-29 Richter Gedeon Nyrt Ipari eljárás szteroid intermedier előállítására
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然の併用ホルモン補充療法剤及び療法
US10098894B2 (en) 2014-07-29 2018-10-16 Therapeuticsmd, Inc. Transdermal cream
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2377418A1 (fr) * 1977-01-13 1978-08-11 Roussel Uclaf Nouveaux derives steroides 4,9-dieniques 11b-substitues, leur procede de preparation et leur application comme medicaments
FR2521565B1 (fr) 1982-02-17 1985-07-05 Dior Sa Parfums Christian Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees
FR2522328B1 (fr) 1982-03-01 1986-02-14 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments
FR2534487B1 (fr) 1982-10-15 1988-06-10 Dior Christian Parfums Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede
ATE151286T1 (de) 1983-11-14 1997-04-15 Columbia Lab Inc Bioadhäsive mittel
FR2598421B1 (fr) 1986-05-06 1988-08-19 Roussel Uclaf Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
US5077211A (en) 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
US5439913A (en) * 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein
US5468741A (en) 1993-05-28 1995-11-21 The Regents Of The University Of California Use of low levels of mifepristone to treat leiomyomata
KR100358319B1 (ko) * 1993-11-16 2002-10-25 쉐링 악티엔게젤샤프트 산화질소 합성효소 기질, 산화질소 공여체, 또는 산화질소저해제를 포함하는 자궁 수축성 질환의 치료용 약물
DE4426601A1 (de) * 1994-07-27 1996-02-01 Schering Ag Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri
DK0806952T3 (da) * 1995-02-02 2003-06-16 Schering Ag Progesteronantagonister til fremstillingen af lægemidler til behandling af dysfunktionelle uterine blødninger
US6900193B1 (en) * 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
WO1997041145A1 (en) * 1996-05-01 1997-11-06 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services 21-substituted progesterone derivatives as new antiprogestational agents
AU2805397A (en) 1996-08-30 1998-03-19 Population Council, Center For Biomedical Research, The Vaginal application mifepristone
US6020328A (en) 1998-03-06 2000-02-01 Research Triangle Institute 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US6172052B1 (en) 1998-12-04 2001-01-09 Research Triangle Institute 17β-acyl-17α-propynyl-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
EP1008443A1 (de) 1998-12-08 2000-06-14 Alusuisse Technology & Management AG Sterilisierbarer Folienverbund für Verpackungszwecke
US6740645B1 (en) 1999-09-03 2004-05-25 Research Triangle Institute 17β-acyl-17α-propynyl-11β-(cyclic amino) aryl steroids and their derivatives having antagonist hormonal properties
DK1265911T3 (da) * 2000-03-17 2008-09-29 Us Gov Health & Human Serv 17-alfa-substitueret-11-beta-substitueret-4-aryl og 21-substitueret 19-norpregnadiendion som antiprogestationelle midler
IN191020B (enExample) * 2000-03-28 2003-09-13 Dabur Res Foundation
ES2225525T3 (es) 2000-04-03 2005-03-16 Astenjohnson, Inc. Componente de atadura prerizado.
DE60115274T2 (de) * 2000-10-18 2006-07-27 Schering Ag Verwendung von antiprogestinen zur prophylaxe und behandlung von hormonabhängigen erkrankungen
CA2453337C (en) 2001-07-09 2012-08-28 Zonagen, Inc. Methods and materials for the treatment of testosterone deficiency in men
ATE461681T1 (de) 2003-04-29 2010-04-15 Gen Hospital Corp Verfahren und vorrichtungen für die verzögerte freisetzung von mehreren arzneimitteln
EP1593376A1 (en) 2004-05-04 2005-11-09 Warner-Lambert Company LLC Improved pullulan capsules
KR101229701B1 (ko) * 2004-07-09 2013-02-05 라보라토이레 에이치알에이 파르마 프로게스테론 수용체 조절제를 함유하는 서방형 조성물
GT200500185A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
DE102005028970A1 (de) * 2005-06-22 2006-12-28 Siemens Ag Piezoakter mit gesteigertem Hubvermögen
DE102005030294A1 (de) * 2005-06-24 2007-01-04 Schering Ag Nichtsteroidale Progesteronrezeptor-Modulatoren
WO2007103510A2 (en) * 2006-03-08 2007-09-13 Danco Laboratories Llc Methods, dosing regimens & medications using anti-progestational agents for the treatment of disorders
EP2078032B1 (en) * 2006-10-24 2017-08-02 Repros Therapeutics Inc. Compositions and methods for suppressing endometrial proliferation
JP2010516686A (ja) * 2007-01-17 2010-05-20 レプロス セラピューティクス インコーポレイティド ステロイド誘導体の安定性向上のための方法
CA2682752C (en) 2007-04-05 2015-07-07 University Of Kansas Rapidly dissolving pharmaceutical compositions comprising pullulan
US8569274B2 (en) * 2007-04-20 2013-10-29 Preglem S.A. Progesterone antagonist and selective progesterone modulator in the treatment of excessive uterine bleeding
TWI477276B (zh) 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
CN103079632A (zh) 2009-09-29 2013-05-01 梅迪梅特里科斯个性化药物传输私人有限公司 用于施用物质的子宫内电子胶囊

Also Published As

Publication number Publication date
AR071516A1 (es) 2010-06-23
EP2293797B1 (en) 2015-11-11
EA201990835A2 (ru) 2019-08-30
AU2009241355B2 (en) 2013-11-14
CA2722753C (en) 2018-07-03
ME01123B (me) 2013-03-20
EP2293797A1 (en) 2011-03-16
MX2010011272A (es) 2010-12-21
CL2009001010A1 (es) 2009-06-19
JP2011518845A (ja) 2011-06-30
NZ589533A (en) 2012-06-29
IL208844A0 (en) 2011-01-31
CN102014923A (zh) 2011-04-13
ES2561810T3 (es) 2016-03-01
MY161059A (en) 2017-04-14
TWI477276B (zh) 2015-03-21
US8735381B2 (en) 2014-05-27
KR20130059442A (ko) 2013-06-05
UA102849C2 (ru) 2013-08-27
CN105616427A (zh) 2016-06-01
BRPI0911563A2 (pt) 2016-07-12
EA032646B1 (ru) 2019-06-28
TW200950786A (en) 2009-12-16
JP5791499B2 (ja) 2015-10-07
US20110046098A1 (en) 2011-02-24
NI201000183A (es) 2012-06-06
EA201071249A1 (ru) 2011-08-30
WO2009134718A8 (en) 2010-09-23
EA201990835A3 (ru) 2019-12-30
EA201401347A1 (ru) 2015-07-30
ZA201007529B (en) 2011-07-27
SG10201408483QA (en) 2015-02-27
AU2009241355A1 (en) 2009-11-05
US8426394B2 (en) 2013-04-23
KR20110014162A (ko) 2011-02-10
CA2722753A1 (en) 2009-11-05
WO2009134718A1 (en) 2009-11-05
US20130289008A1 (en) 2013-10-31

Similar Documents

Publication Publication Date Title
DK2293797T3 (en) PROGESTERON ANTAGONISTS SUCH AS CDB-4124 TO REDUCE PAIN CONNECTED WITH ENDOMETRIOSIS AND UTERUS FIBROMES
EP2078032B1 (en) Compositions and methods for suppressing endometrial proliferation
US20090118253A1 (en) Compositions and methods for treating dysfunctional uterine bleeding
RS56491B1 (sr) Kompozicije i postupci za supresiju proliferacije endometrijuma
HK1225606A1 (en) Progesterone antagonists such as cdb-4124 in the treatment of endometriosis, uterine fibroids, dysmenorrhea, breast cancer
HK1225606A (en) Progesterone antagonists such as cdb-4124 in the treatment of endometriosis, uterine fibroids, dysmenorrhea, breast cancer
HK1155085A (en) Progesterone antagonists such as cdb-4124 in the treatment of endometriosis, uterine fibroids, dysmenorrhea, breast cancer etc
HK1135111A (en) Compositions and methods for suppressing endometrial proliferation